Edition:
United Kingdom

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

68.95USD
25 Jun 2018
Change (% chg)

$-2.25 (-3.16%)
Prev Close
$71.20
Open
$70.15
Day's High
$70.90
Day's Low
$67.40
Volume
38,441
Avg. Vol
179,427
52-wk High
$71.25
52-wk Low
$17.60

Latest Key Developments (Source: Significant Developments)

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

Regenxbio Provides Year-End 2017 Corporate Update
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Regenxbio Inc ::REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE.- ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​.- ‍ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018​.- ‍ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.  Full Article

Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II.REGENXBIO INC - ‍EXPECT TO COMMENCE TRIAL ENROLLMENT IN FIRST HALF OF 2018 FOR RGX-121​.  Full Article

Regenxbio reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - ‍cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016​.  Full Article

Regenxbio reports Q2 loss per share $0.55
Tuesday, 9 Aug 2016 

Regenxbio Inc : Q2 loss per share $0.55 . Q2 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S . Regenxbio reports second quarter 2016 financial results and recent operational highlights .Q2 revenue $2.4 million versus I/B/E/S view $2 million.  Full Article

Swiss stocks - Factors to watch on June 12

ZURICH, June 12 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8,643 points on Tuesday, according to premarket indications by bank Julius Baer .